Potomac Fund Management’s AstraZeneca AZN Stock Holding History

Potomac Fund Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.97M	Hold	10,398	–	–	0.05%	36
2026 Q1	$2.05M	Buy	10,398 +29	+0.3%	+$5.59K	0.07%	31
2025 Q4	$1.91M	Sell	10,369 -393	-4%	-$68.9K	0.07%	35
2025 Q3	$1.65M	Sell	10,762 -92	-0.8%	-$13.9K	0.07%	42
2025 Q2	$1.52M	Buy	+10,854	New	+$1.52M	0.09%	41
2025 Q1	–	Sell	-8,382	Closed	-$1.1M	–	80
2024 Q4	$1.1M	Buy	+8,382	New	+$1.17M	0.06%	47

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Potomac Fund Management's AZN Position: Q2 2026 in Review

Potomac Fund Management held its AstraZeneca (AZN) position steady in Q2 2026 at 10,398 shares worth $1.97M. The position accounts for 0.05% of the portfolio, ranked #36.

Potomac Fund Management first reported a position in AZN in Q4 2024 and has held it in 6 quarters since. The position peaked at $2.05M in Q1 2026. 1,495 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

Potomac Fund Management held 10,398 shares of AstraZeneca worth $1.97M as of Q2 2026.
Potomac Fund Management left its AstraZeneca share count unchanged in Q2 2026.
AstraZeneca made up 0.05% of Potomac Fund Management's portfolio in Q2 2026, its #36 holding.
Potomac Fund Management first reported a position in AstraZeneca in Q4 2024 and has held it in 6 quarters since.
Potomac Fund Management's AstraZeneca position peaked at $2.05M in Q1 2026.
1,495 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Potomac Fund Management's 13F filing for Q2 2026, filed 13 Aug 2026.